Health
Novartis to Invest $100m to Research, Develop New Antimalarials
By Modupe Gbadeyanka
The management of Novartis has announced a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting.
Further, the company has released new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.
Over the next five years, as part of its commitment, Novartis will invest more than $100 million to advance research and development of next-generation treatments to combat emerging resistance to artemisinin and other currently used antimalarials.
The company will also implement an equitable pricing strategy to maximize patient access in malaria-endemic countries when these new treatments become available.
In order to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90 percent by 2030, Novartis will further help expand access to pediatric antimalarials and implement healthcare system strengthening programs in 4 sub-Saharan countries.
“Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments,” said Vas Narasimhan, CEO of Novartis. “At the same time, we need to work to ensure that our innovation reaches those most in need, even those in the most remote locations.”
The R&D investment is meant to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for our novel antimalarial drug candidates KAF156 and KAE609 (currently in Phase IIb and Phase IIa respectively). Both are from new classes of medicines that were selected for their ability to treat malaria in different ways from current therapies. The investment also includes new uses of technology to identify areas where the malaria burden is greatest. This information could then be used to support capability- and capacity-building to establish future clinical trial sites, so the medicines can be evaluated in the populations where they are most needed.
In order to enable patients in malaria-endemic countries to afford these new treatments once they become available, the company will implement an equitable pricing strategy based on socio-economic conditions of different population segments. We plan to do so in consultation with our development and funding partners and other stakeholders.
Despite the tremendous progress made in combating malaria, one child still dies from the disease every two minutes. Novartis aims to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90 percent in 2030. In Nigeria, the Democratic Republic of Congo and at least two more countries in sub-Saharan Africa that bear the highest number of malaria-related child deaths, we plan to work with partners to help expand access to our paediatric artemisinin-based combination therapy (ACT) and drive integrated community case management (iCCM) initiatives.
iCCM is recognized as a key strategy for increasing access to essential treatments and reducing child mortality from treatable conditions, such as malaria, pneumonia and diarrhoea.
Novartis has been committed to the fight against malaria for the past two decades, launching the first fixed-dose ACT in 1999 and the first dispersible paediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.
To date, working with partners, the company has delivered more than 850 million treatments, including 350 million paediatric treatments, without profit to malaria-endemic countries.
The new commitment launches at the same time as results from a new research study (Malaria Futures for Africa, MalaFA) across 14 countries in sub-Saharan Africa.
In total, 68 African experts from governments, the research community and nongovernmental organizations expressed their views on progress and remaining challenges toward the 2030 global malaria elimination targets.
Global malaria deaths have fallen by more than 60 percent between 2000 and 2015. Yet respondents fear progress could stall unless national governments provide more funding and international organizations target their support more effectively.
Many experts also voiced concerns that mosquitoes were increasingly resistant to insecticides and that malaria parasites could become resistant to ACTs in the next 15-20 years. Some feared that resistance would spread faster because of expanding trade and travel between Africa and Asia, where the first signs of drug resistance are emerging. Others thought it was just as likely that resistance could emerge independently in Africa.
Respondents expressed widespread support for making better use of the currently available tools, while stressing that more emphasis should be placed on improving the delivery of existing and new interventions to fight malaria – an area currently underfunded.
The MalaFA study was commissioned by Novartis and co-chaired by Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust program, Kenya and University of Oxford, United Kingdom. Research advisers include Roll Back Malaria, Malaria No More UK and the African Leaders Malaria Alliance.
According to the 2017 World Malaria Report, there were 216 million cases of malaria in 2016, up from 211 million cases in 2015. The number of malaria deaths was 445,000 in 2016 vs. 438,000 in 2015. Ninety percent of malaria cases and over 90 percent of malaria deaths occur in sub-Saharan Africa. Children under 5 are particularly at risk, and malaria takes the life of a child every two minutes.
Health
Mums Feel Warmth Initiative Raises Postpartum Depression Awareness
By Modupe Gbadeyanka
A transformative webinar to raise awareness on postpartum depression (PPD) by nursing mothers has been organised by MSc Media and Communication students from the School of Media and Communications of the Pan-Atlantic University.
The programme titled Beyond Baby Blues: Understanding and Overcoming Postpartum Depression was held on January 7, 2025.
It was put together by the students under the Mums Feel Warmth initiative, with experts in the field invited to speak on the matter aimed at empowering mothers and fostering a sense of reassurance.
The webinar was to highlight the journey through postpartum depression, offering a message of hope, resilience, and the importance of mental health support for mothers everywhere.
One of the speakers, Dr Laja Odunuga, who is the Care Coordinator for AVON HMO, explained the difference between the common “baby blues” and the more severe, long-lasting PPD.
The discussion highlighted how PPD can manifest not just as sadness but through severe fatigue, disconnection from the newborn, and loss of interest in activities, which can last well beyond the typical two-week period associated with baby blues.
Another expert, Ms Otomfon Ibanga, the Assistant Lead Nurse for Q-Life Family Clinic, emphasised the role of support systems, urging families and friends to be vigilant for signs of PPD and to provide a nurturing environment.
She also discussed prevention strategies, including prenatal planning for support structures and post-delivery management through therapy or medication.
On his part, Dr Chimaraoke Obialo, who is the Medical Director of Life Amada Health Consultancy, addressed the stigma surrounding PPD, advocating for education to transform societal perceptions from judgement to support.
The webinar underscored the need for community involvement, not just in recognising symptoms but in actively participating in the healing process by offering emotional and practical support.
The Mums Feel Warmth webinar was more than just an educational session; it was a call to action for society to embrace and support new mothers dealing with PPD.
By fostering open conversations and providing platforms for sharing experiences, Mums Feel Warmth continues to lead the charge against the stigma of PPD.
The commitment shown by the panellists and attendees alike promises a future where every mother has access to the understanding and care needed to navigate through the complexities of postpartum depression, ensuring that the joy of motherhood is not overshadowed by mental health challenges.
Mums Feel Warmth, with its core values of empathy, compassion, hope, community, and education, speaks to the Sustainable Development Goal 3, advocating for good health and well-being.
The initiative is breaking the silence around PPD, a condition that can significantly impact new mothers in the critical period following childbirth.
Health
NCDC Monitors HMPV Situation, Affirms Nigeria at Moderate Risk
By Adedapo Adesanya
The Nigeria Centre for Disease Control (NCDC) says the country is at “moderate” risk for Human Metapneumovirus (HMPV), a virus that leads to an upper respiratory tract infection with symptoms like cough, fever, and nasal congestion.
In a public health advisory, the Nigerian health agency said the federal government is closely monitoring the outbreak of the virus and is taking safety measures to “strengthen the country’s preparedness and response capacity”.
Recent reports indicate a significant rise in HMPV cases in China, as well as increased respiratory infections linked to HMPV in countries such as the United Kingdom (UK), France, and Germany, particularly during the winter season.
The NCDC said it conducted a risk assessment for the HMPV in collaboration with the Federal Ministry of Health and partners such as the World Health Organization (WHO), the US Centres for Disease Control and Prevention (USCDC), and the UK Health Security Agency (UKHSA).
“The assessment classified the risk of HMPV for Nigeria as moderate. This evaluation will inform and guide preparedness efforts, decision-making, and response strategies to mitigate potential impacts,” the advisory said.
It said the NCDC is working to give Nigerians “timely, accurate information and guidance to keep the Nigerian public informed and prepared”.
NCDC noted that it “in collaboration with Port Health Authorities, is taking proactive steps to ensure robust preparedness at all international points of entry (PoEs) in response to the dynamic risk assessment for Human Metapneumovirus (HMPV).
“These measures are designed to mitigate the potential risk of HMPV transmission through international travel.”
HMPV was first identified in the Netherlands in 2001 and the virus spreads through direct contact between people or when someone touches surfaces contaminated with it.
Children under two are most vulnerable to the virus alongside those with weakened immune systems such as the elderly and those with advanced cancer, according to medical experts.
There have also been worries that this could be like COVID-19, but experts have eased the fear as they are not similar because pandemics are typically caused by novel pathogens, which is not the case for HMPV.
Health
Digitising Healthcare With Local Realities in Mind: Shaping The Future of Healthcare in Africa
eHealth Africa (eHA) has urged governments and stakeholders to explore the critical factors beyond technology that are essential for the deployment of digital health solutions for the long-term success of public health systems across Africa. Data-backed interventions will help streamline operations and enable the formulation of interventions that appreciate the cultural norms when addressing the immediate needs of different communities within the region.
Speaking during a panel session at the Global Digital Health Forum 2024 in Nairobi, eHealth Africa’s Executive Director Atef Fawaz emphasised the importance of integrating technology with local cultures and addressing community-specific needs. “Understanding the unique healthcare challenges in each country allows us to deploy tech solutions that truly make an impact.”For instance, eHealth Africa successfully delivered over 5.8 million vaccines (5,801,209) to 351 primary healthcare facilities across states in Nigeria which was made possible through the deployment of the innovative Logistics Management Information System (LoMIS) application.
“The system significantly improved the availability of vaccines for Routine Immunisation (RI), ensuring timely and efficient distribution while eliminating stockouts at primary healthcare facilities. This intervention highlights our commitment to strengthening immunisation programs and enhancing healthcare delivery at the grassroots level,” he said.
In his contribution, Abdulhamid Yahaya, the Deputy Director of Global Health Informatics highlighted the need to understand the local cultural, social, and regulatory landscape to build solutions that are designed with local realities in mind.
eHealth Africa Board Member Micheline Ntiru said using technology provided stakeholders among them global health leaders, tech innovators, and development experts as well as local communities a platform to create the right solutions that work within the constraints of each community, and with the support of local leadership.
For instance, local health workers have been using mobile-based reminder systems to improve compliance and overall health outcomes while some local immunisation centres have been sending SMS reminders to parents as well as to provide educational messages about the diseases they protect against. Mobile phones, now available in nearly 80 per cent of African homes, can also be used during emergencies to dispatch mass announcements about satellite clinic locations and schedules.
According to the World Health Organisation, increased use of the Internet, email, social networking sites and availability of mobile phones facilitates the deployment of eHealth solutions, applications and services towards the improvement of national health systems. The use of technological eHealth solutions could also be used to encourage positive lifestyle changes to prevent and control common diseases.
The panel moderated by Ota Akhigbe, Director of Partnerships and Programs comprised of Ms Ntiru (Delta40 ventures), Mr Yahaya (eHealth Africa), Chief Impact Officer at Tiko – Serah Malaba, Dr Olamide Okulaja (Maisha Meds), Audere Chief Executive Officer Dr Dino Rech, and Rachel Alladian from Jacaranda. They discussed how strategic partnerships, regulatory compliance, and a deep understanding of local contexts are crucial for driving digital health innovations that can succeed in diverse regions.
The GDHF forum was attended by health scholars, researchers, and representatives from the Ministry of Health in Ethiopia, Tanzania, Kenya, Malaysia, Somalia and Sri Lanka as well as representatives from the World Bank, medicine manufacturers, technology vendors, UN agencies among others.
-
Feature/OPED5 years ago
Davos was Different this year
-
Travel/Tourism8 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz2 years ago
Estranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years ago
Sort Codes of GTBank Branches in Nigeria
-
Economy2 years ago
Subsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking2 years ago
First Bank Announces Planned Downtime
-
Sports2 years ago
Highest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
-
Technology4 years ago
How To Link Your MTN, Airtel, Glo, 9mobile Lines to NIN